---
schema_version: "secwatch.filing_event.v1"
accession: "0001808665-23-000049"
form_type: "8-K"
ticker: "ASRT"
cik: "0001808665"
company_name: "Assertio Holdings, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T09:10:12.725111+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Assertio Q2 sales up 13% to $40.1M; closes Spectrum buy; withdraws guidance on generic Indocin

## Summary
- Net product sales $40.1M (+13% YoY); GAAP net income $8.5M ($0.13 EPS), adjusted EPS $0.19 vs $0.28 YoY.
- Acquisition of Spectrum closed July 31; ROLVEDON Q2 sales $21.0M, launch trajectory strong.
- Cash from operations $18.6M; cash and equivalents $70.2M at quarter end.
- 2023 financial guidance withdrawn after FDA approval of generic indomethacin suppository.
- SG&A $16.8M, up from $10.5M, includes $3.4M transaction costs vs $2.0M insurance benefit last year.

## SEC filing metadata
- accession: 0001808665-23-000049
- form_type: 8-K
- ticker: ASRT
- cik: 0001808665
- company_name: Assertio Holdings, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808665/000180866523000049/0001808665-23-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808665/000180866523000049/asrt-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808665-23-000049
- JSON: https://secwatch.observer/filing/0001808665-23-000049.json
- Plain text: https://secwatch.observer/filing/0001808665-23-000049.txt

## Key facts
- Earnings Releases
  Assertio Holdings, Inc. reported second quarter ended June 30, 2023 results: revenue $40.1 million, net income $8.5 million, EPS $0.13.
  - Period: second quarter ended June 30, 2023
  - Revenue: $40.1 million
  - Net income: $8.5 million
  - EPS: $0.13
  - Result: reported results
  source text: Per Share (Non-GAAP) 2 $ 0.19 $ 0.28 $ 0.48 $ 0.66 Second quarter results included the following as compared to the prior year quarter: • Net product sales increased 13% , to $40.1 million. ◦ Increased sales of Indocin and Otrexup plus the addition of Sympazan more than offset the expected decline in Cambia. ◦ Sympazan achieved new peaks in both quarterly and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808665/000180866523000049/0001808665-23-000049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.